08:30 AM EST, 03/03/2025 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) reported a Q4 net loss Monday of $0.42 per diluted share.

Analysts polled by FactSet expected a loss of $0.37.

As expected, the company did not report any revenue for the quarter ended Dec. 31. Meanwhile, operating expenses were $45.5 million for the quarter.

The clinical-stage biopharmaceutical firm said it ended Q4 with $470.2 million in cash, cash equivalents and marketable securities, which it expects to fund its current operating plan for "at least the next 12 months."